NASDAQ:ORTX - Orchard Therapeutics Stock Price, News & Analysis

+0.03 (+0.22 %)
(As of 08/25/2019 07:17 AM ET)
Today's Range
Now: $13.76
50-Day Range
MA: $13.54
52-Week Range
Now: $13.76
Volume62,168 shs
Average Volume171,531 shs
Market Capitalization$1.18 billion
P/E RatioN/A
Dividend YieldN/A
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. Its commercial stage products include Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Ltd. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:ORTX



Sales & Book Value

Annual Sales$2.08 million
Book Value$4.32 per share



Market Cap$1.18 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive ORTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ORTX and its competitors with MarketBeat's FREE daily newsletter.

Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions

What is Orchard Therapeutics' stock symbol?

Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics PLC - (NASDAQ:ORTX) issued its earnings results on Thursday, August, 8th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.20. View Orchard Therapeutics' Earnings History.

What price target have analysts set for ORTX?

4 Wall Street analysts have issued 1-year target prices for Orchard Therapeutics' shares. Their predictions range from $21.00 to $27.00. On average, they anticipate Orchard Therapeutics' share price to reach $24.50 in the next twelve months. This suggests a possible upside of 78.1% from the stock's current price. View Analyst Price Targets for Orchard Therapeutics.

What is the consensus analysts' recommendation for Orchard Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Orchard Therapeutics.

Has Orchard Therapeutics been receiving favorable news coverage?

News stories about ORTX stock have trended positive this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Orchard Therapeutics earned a news impact score of 2.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the immediate future. View News Stories for Orchard Therapeutics.

Are investors shorting Orchard Therapeutics?

Orchard Therapeutics saw a decrease in short interest in July. As of July 15th, there was short interest totalling 1,682,800 shares, a decrease of 19.8% from the June 15th total of 2,099,500 shares. Based on an average daily trading volume, of 207,100 shares, the short-interest ratio is currently 8.1 days. Approximately 2.6% of the company's shares are sold short. View Orchard Therapeutics' Current Options Chain.

Who are some of Orchard Therapeutics' key competitors?

What other stocks do shareholders of Orchard Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Range Resources (RRC), Callon Petroleum (CPE), Alerian MLP ETF (AMLP), Coeur Mining (CDE), Zynerba Pharmaceuticals (ZYNE), AMBEV S A/S (ABEV), Apache (APA), Eversource Energy (ES), OFG Bancorp (OFG) and Direct Line Insurance Group (DLG).

Who are Orchard Therapeutics' key executives?

Orchard Therapeutics' management team includes the folowing people:
  • Mr. Mark A. Rothera, CEO, Pres & Director (Age 56)
  • Dr. Anne Dupraz-Poiseau, Chief Regulatory Officer
  • Mr. Frank E. Thomas, CFO & Chief Bus. Officer (Age 49)
  • Ms. Ran Zheng, Chief Technical Officer
  • Prof. Bobby Gaspar Ph.D., M.D., Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 54)

When did Orchard Therapeutics IPO?

(ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Orchard Therapeutics' major shareholders?

Orchard Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (4.71%), Cowen Inc. (3.54%), Cowen Inc. (3.54%), Vivo Capital LLC (1.53%), Putnam Investments LLC (1.35%) and Westfield Capital Management Co. LP (1.22%).

Which institutional investors are selling Orchard Therapeutics stock?

ORTX stock was sold by a variety of institutional investors in the last quarter, including VHCP Management III LLC and Parametric Portfolio Associates LLC.

Which institutional investors are buying Orchard Therapeutics stock?

ORTX stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Vivo Capital LLC, Putnam Investments LLC, Westfield Capital Management Co. LP, Artal Group S.A., Balyasny Asset Management LLC, Monashee Investment Management LLC and Alps Advisors Inc..

How do I buy shares of Orchard Therapeutics?

Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Orchard Therapeutics' stock price today?

One share of ORTX stock can currently be purchased for approximately $13.76.

How big of a company is Orchard Therapeutics?

Orchard Therapeutics has a market capitalization of $1.18 billion and generates $2.08 million in revenue each year. The company earns $-230,490,000.00 in net income (profit) each year or ($10.22) on an earnings per share basis. Orchard Therapeutics employs 180 workers across the globe.View Additional Information About Orchard Therapeutics.

What is Orchard Therapeutics' official website?

The official website for Orchard Therapeutics is

How can I contact Orchard Therapeutics?

Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 44-20-3384-6700.

MarketBeat Community Rating for Orchard Therapeutics (NASDAQ ORTX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  184
MarketBeat's community ratings are surveys of what our community members think about Orchard Therapeutics and other stocks. Vote "Outperform" if you believe ORTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by Staff

Featured Article: What is Compound Interest?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel